Article thumbnail

Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer

By Karen S. Kelly-Spratt, Sharon J. Pitteri, Kay E. Gurley, Denny Liggitt, Alice Chin, Jacob Kennedy, Chee-Hong Wong, Qing Zhang, Tina Busald Buson, Hong Wang, Samir M. Hanash and Christopher J. Kemp


Tumor development is accompanied by a complex host systemic response, which includes inflammatory and angiogenic reactions. Both tumor-derived and systemic response proteins are detected in plasma from cancer patients. However, given their non-specific nature, systemic response proteins can confound the detection or diagnosis of neoplasia. Here, we have applied an in-depth quantitative proteomic approach to analyze plasma protein changes in mouse models of subacute irritant-driven inflammation, autoreactive inflammation, and matrix associated angiogenesis and compared results to previously described findings from mouse models of polyoma middle T-driven breast cancer and Pdx1-Cre KrasG12D Ink4a/Arf lox/lox -induced pancreatic cancer. Among the confounding models, approximately 1/3 of all quantified plasma proteins exhibited a significant change in abundance compared to control mice. Of the proteins that changed in abundance, the majority were unique to each model. Altered proteins included those involved in acute phase response, inflammation, extracellular matrix remodeling, angiogenesis, and TGFβ signaling. Comparison of changes in plasma proteins between the confounder models and the two cancer models revealed proteins that were restricted to the cancer-bearing mice, reflecting the known biology of these tumors. This approach provides a basis for distinguishing between protein changes in plasma that are cancer-related and those that are part of a non-specific host response

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A mouse model repository for cancer biomarker discovery.
  2. (2008). A mouse to human search for plasma proteome changes associated with pancreatic tumor development.
  3. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
  4. (2007). Angiogenesis and chronic inflammation: cause or consequence?
  5. (1977). Autoimmunity to type II collagen an experimental model of arthritis.
  6. (2001). Biomedicine. Clotting factors build blood vessels.
  7. (2002). Cancer immunoediting: from immunosurveillance to tumor escape.
  8. (2006). Complement activation induces dysregulation of angiogenic factors and causes fetal loss.
  9. (2006). Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments.
  10. (2003). Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3.
  11. (2010). Ding A
  12. (2002). Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.
  13. (2007). Extracellular control of TGFbeta signalling in vascular development and disease.
  14. (2008). Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production.
  15. (2006). General framework for developing and evaluating database scoring algorithms using the TANDEM search engine.
  16. (2003). Haptoglobinalpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
  17. (1993). Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.
  18. (2002). Inflammation and cancer.
  19. (2009). Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
  20. (2006). Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
  21. (2007). Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer.
  22. (2009). Lipocalin 2 promotes breast cancer progression.
  23. (2007). Loss of fibulin-2 expression is associated with breast cancer progression.
  24. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis.
  25. (1994). Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils.
  26. (2008). Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer.
  27. (2003). NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.
  28. (2004). Nuclear factor-kappaB regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model.
  29. (1998). Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis.
  30. (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
  31. (2006). Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
  32. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.
  33. (2008). Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells.
  34. (2003). Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.
  35. (2006). Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS.
  36. (2005). Resolution of inflammation: the beginning programs the end.
  37. (1996). Role of cytokines in rheumatoid arthritis.
  38. (2006). Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
  39. (2002). Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes.
  40. (2010). Systemic inflammation as a confounding factor in cancer biomarker discovery and validation.
  41. (2004). TANDEM: matching proteins with tandem mass spectra.
  42. (2003). The case for early detection.
  43. (2009). The effect of thrombospondin-1 on breast cancer metastasis.
  44. (2004). The International Protein Index: an integrated database for proteomics experiments.
  45. (2005). The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
  46. (1998). The performance of screening tests for ovarian cancer: results of a systematic review.
  47. (2002). The sponge/Matrigel angiogenesis assay.
  48. (2006). The US Food and Drug Administration perspective on cancer biomarker development.
  49. (2006). Transforming growth factor-beta in cancer and metastasis.
  50. (1995). Tumor angiogenesis as a predictor of recurrence in gastric carcinoma.
  51. (2005). Utilizing human blood plasma for proteomic biomarker discovery.